Cancer patients get continued access to promising drug in rollover study
NCT ID NCT02934568
First seen Feb 04, 2026 · Last updated May 24, 2026 · Updated 20 times
Summary
This study allows cancer patients who were already benefiting from the drug ribociclib in a previous Novartis trial to keep receiving it. The goal is to provide continued access to the treatment and monitor how long patients stay on it, as well as any side effects. Only 22 patients are enrolled, and they must have shown clinical benefit from the drug in the earlier study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONTINUED ACCESS TO STUDY TREATMENT(S), CANCERS WITH A MASS, BULKY TUMOR, NODULE, LUMP, ADVANCED CANCER, ADVANCED SOLID TUMORS, ADVANCED SOLID MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Broome Oncology
Johnson City, New York, 13790, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Novartis Investigative Site
Lyon, 69373, France
-
Novartis Investigative Site
Villejuif, 94800, France
-
Novartis Investigative Site
Cologne, North Rhine-Westphalia, 50937, Germany
-
Novartis Investigative Site
Singapore, 119228, Singapore
-
Novartis Investigative Site
Madrid, 28041, Spain
-
Novartis Investigative Site
Madrid, 28050, Spain
-
Novartis Investigative Site
Tainan, 704302, Taiwan
-
Novartis Investigative Site
Taipei, 10002, Taiwan
-
St Jude Childrens Research Hospital
Memphis, Tennessee, 38105, United States
-
The Regents of the Uni of Michigan
Ann Arbor, Michigan, 48109-5930, United States
-
University Of Alabama At Birmingham
Birmingham, Alabama, 35294-3300, United States
Conditions
Explore the condition pages connected to this study.